D1 Capital Partners’s Exact Sciences EXAS Stock Holding History

D1 Capital Partners’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-275,000	Closed	-$25.4M	–	38
2019 Q4	$25.4M	Buy	+275,000	New	+$24.2M	0.37%	23

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D1 Capital Partners's EXAS Position: Q1 2020 in Review

D1 Capital Partners sold out of Exact Sciences (EXAS) in Q1 2020, closing a stake of 275,000 shares — an estimated $25.4M sold.

D1 Capital Partners first reported a position in EXAS in Q4 2019 and held it in 1 quarter. The position peaked at $25.4M in Q4 2019. 475 funds tracked by Wall St. Rank hold EXAS as of Q1 2020.

D1 Capital Partners reported no remaining Exact Sciences position as of Q1 2020 after selling out during the quarter.
D1 Capital Partners sold 275,000 Exact Sciences shares in Q1 2020, an estimated $25.4M.
D1 Capital Partners first reported a position in Exact Sciences in Q4 2019 and held it in 1 quarter.
D1 Capital Partners's Exact Sciences position peaked at $25.4M in Q4 2019.
475 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2020.

Based on D1 Capital Partners's 13F filing for Q1 2020, filed 15 May 2020.